



Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsLtd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

Date: 27.05.2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400001.

Scrip Code: 538965

Sub: Outcome of Board Meeting held on 27.05.2026 pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company was held on 27.05.2026, wherein the Board inter alia:

1. Considered and approved the Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March, 2026.
2. Took note of the Auditors Report issued by the Statutory Auditors of the Company on the aforesaid financial results.

Further, the financial results are also available on the website of the Company at Concord Drugs Limited > Investor Relations and on the website of BSE Limited.

The financial results will also be published in the newspapers as per the requirements and in the format prescribed under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 03:00 PM and concluded at 04:15 PM.

This is for your information and records.

Thanking you,

Yours faithfully,

For Concord Drugs Limited

Seelam Manoj Kumar Reddy
Whole-time Director
DIN: 06991382

Concord Drugs Limited


Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

Statement of assets and Liabilities audited (Consolidated) for the year ended 31.03.2026

Rs in lakhs

Particulars	Note	Consolidated	
		31-Mar-26	31-Mar-25
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	1,093.77	1,157.21
(b) Capital Work-in Progress	3	243.11	199.65
(c) Investment property	3	63.95	63.95
(d) Goodwill	4	-	-
Financial assets			
(a) Investments	4	78.25	80.01
(b) Loans & Advances	4	7.89	7.89
Other Non current assets	5	670.63	929.26
Total Non - Current Assets		2,157.61	2,437.97
Current Assets			
Inventories	7	2,551.60	2,526.87
Financial assets			
(a) Investments			
(b) Trade receivables	6	2,438.15	1,360.48
(c) Cash and cash equivalents	8	27.81	12.09
(d) Bank balances other than (c) above	8	47.24	10.45
(e) Other Current Financial Assets	9	3.77	12.10
Other current assets	10	262.59	154.21
Total Current assets		5,331.16	4,076.21
Total Assets		7,488.76	6,514.18
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	1,317.50	1,000.00
Other equity	12	3,533.89	2,411.36
Total Equity		4,851.39	3,411.36
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	180.59	132.44
(b) Trade payables		15.73	17.93
Deferred tax liabilities, net	14	62.40	62.56
Provisions	15	271.88	271.88
Government Grants	13		
Total Non-current liabilities		530.60	484.80
Current liabilities			
Financial liabilities			
(a) Borrowings	16	1,179.33	1,586.82
(b) Trade payables	17	707.10	762.24
(c) Other Current financial liabilities	18	90.88	205.12
Current tax liabilities, net	15	41.34	20.58
Other current liabilities	19	88.13	43.25
Total Current liabilities		2,106.77	2,618.02
Total liabilities		2,637.37	3,102.82
Total Equity and liabilities		7,488.76	6,514.18

Nagi Reddy Seelam
Managing Director
DIN: 01764665




Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Audited Statement Of Consolidated Profit and Loss for the Period ended 31st March '26

Amount in Lakhs


	Particulars	Note	Consolidated	
			31-Mar-26	31-Mar-25
I	Revenue from Operations			
	a. Net sales from Operations	20	7,873.68	4,524.46
II	Other Income	21	3.44	1.44
III	Total Revenue (I+II)		7,877.13	4,525.91
IV	Expenses			
	a. Cost of Material Consumed	22	6,802.96	3,581.09
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-38.37	-58.05
	c. Employees Benefit Expenses	24	497.05	463.45
	d. Finance Costs	25	171.37	202.67
	e. Depreciation and Amortisation expense	3	136.67	143.08
	f. Other expenses	26	160.13	124.54
	Total Expenses		7,729.81	4,456.77
	Profit/ (Loss) before Exceptional item and tax (III-IV)		147.32	69.14
V	Exceptional Items		-	-
VI	Profit/ (Loss) before tax (V+VI)		147.32	69.14
VII	Tax Expense:		41.82	35.52
VIII	a. Current tax		41.98	20.29
	b. Deferred tax charge/credit		-0.16	15.23
IX	Profit/ (Loss) for the period (VII-VIII)		105.50	33.62
X	Other Comprehensive Income		-	-
	Items that will not be reclassified to profit or loss		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		105.50	33.62
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		1,317.50	1,000.00
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		0.95	0.34
	b. Diluted (in Rs)		0.95	0.34

Nagi Reddy Seelam
Managing Director
DIN: 01764665



Concord Drugs Limited			
Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana			
Statement of standalone assets and Liabilities for the year ended 31.03.2026			
Rs In lakhs			
Particulars	Note	31-Mar-26	31-Mar-25
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	1,091.02	1,153.51
(b) Capital Work-in Progress	3	243.11	199.65
(b) Investment property	3	63.95	63.95
Financial assets			
(a) Investments	4	161.50	161.50
(b) Loans & Advances	4	7.89	7.89
Other Non current assets	5	670.63	929.26
Total Non - Current Assets		2,238.10	2,515.76
Current Assets			
Inventories	7	1,834.99	1,912.62
Financial assets			
(a) Investments			
(b) Trade receivables	6	2,812.88	1,267.33
(c) Cash and cash equivalents	8	27.10	11.54
(d) Bank balances other than (c) above	8	47.24	10.45
(e) Other Current Financial Assets	9	3.77	12.10
Other current assets	10	221.41	128.35
Total Current assets		4,947.38	3,342.40
Total Assets		7,185.48	5,858.16
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	1,317.50	1,000.00
Other equity	12	3,533.89	2,411.36
Total Equity		4,851.39	3,411.36
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	180.59	130.80
(b) Trade payables		15.73	17.93
Deferred tax liabilities, net	14	63.50	63.72
Provisions	15	271.88	271.88
Government Grants	13	-	-
Total Non-current liabilities		531.69	484.33
Current liabilities			
Financial liabilities			
(a) Borrowings	16	980.45	1,355.18
(b) Trade payables	17	602.49	340.66
(c) Other Current financial liabilities	18	90.88	205.12
Current tax liabilities, net	15	41.34	18.99
Other current liabilities	19	87.24	42.52
Total Current liabilities		1,802.40	1,962.48
Total liabilities		2,334.09	2,446.80
Total Equity and liabilities		7,185.48	5,858.16

Nagi Reddy Seelam
Managing Director
DIN: 01764665




Statement Of Standalone Profit and Loss for the Year ended 31.03.2026

Rs in lakhs

	Particulars	Note	31-Mar-26	31-Mar-25
I	Revenue from Operations			
	a. Net sales from Operations	20	7,584.86	3,693.21
II	Other Income	21	3.44	1.44
III	Total Revenue (I+II)		7,588.30	3,694.65
IV	Expenses			
	a. Cost of Material Consumed	22	6,449.85	2,822.46
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	63.98	-58.05
	c. Employees Benefit Expenses	24	489.91	439.13
	d. Finance Costs	25	145.91	171.84
	e. Depreciation and Amortisation expense	3	135.72	141.80
	f. Other expenses	26	158.07	113.34
	Total Expenses		7,443.44	3,630.52
	Profit/ (Loss) before Exceptional item and tax (III-IV)		144.86	64.13
V	Exceptional Items		-	-
VI	Profit/ (Loss) before tax (V+VI)		144.86	64.13
VII	Tax Expense:		41.12	34.56
VIII	a. Current tax		41.34	18.99
	b. Deferred tax charge/credit		-0.22	15.57
IX	Profit/ (Loss) for the period (VII-VIII)		103.74	29.57
X	Other Comprehensive Income		-	-
	Items that will not be reclassified to profit or loss		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		103.74	29.57
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		1,317.50	1,000.00
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		0.93	0.30
	b. Diluted (in Rs)		0.93	0.30

Nagi Reddy Seelam
Managing Director
DIN: 01764665



STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March 2026

[Rs. in Lakhs]

Particulars	Quarterly ended				Year Ended	
	31-Mar-26 (Audited)	31-Dec-25 (Un Audited)	31-Mar-25 (Audited)	31-Mar-26 (Audited)	31-Mar-25 (Audited)	31-Mar-25 (Audited)
I Revenue from Operations						
a. Net sales From Operations	3,555.22	1,684.01	796.40	7,584.86	3,693.21	
b. Other Operating Income	1.08	2.12	0.48	3.44	1.44	
II Other Income						
III Total Revenue (I+II)	3,556.31	1,686.13	796.88	7,588.30	3,694.65	
IV Expenses						
a. Cost of Material Consumed	3,180.79	1,433.24	604.42	6,449.85	2,822.46	
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	7.08	0.77	-7.49	63.98	-58.05	
c. Employees Benefit Expenses	172.61	122.19	153.31	489.91	439.13	
d. Finance Costs	34.46	29.60	53.48	145.91	171.84	
e. Depreciation and Amortisation expense	35.05	30.44	37.46	135.72	141.80	
f. Other expenses	52.85	40.61	20.64	158.07	113.34	
Total Expenses	3,482.84	1,656.85	794.82	7,443.44	3,630.52	
V Profit/ (Loss) before Exceptional Item and tax (III-IV)	73.47	29.28	2.06	144.86	64.13	
Exceptional Items	-	-	-	-	-	
VI Profit/ (Loss) before tax (V-VI)	73.47	29.28	2.06	144.86	64.13	
VII Tax Expense:						
a. Current tax	21.79	7.76	1.26	41.12	34.56	
b. Deferred tax charge/credit	21.32	7.07	-0.67	41.34	18.99	
IX Profit/ (Loss) for the period (VII-VIII)	0.47	0.69	1.93	-0.22	15.57	
X Other Comprehensive Income	51.68	21.52	0.80	103.74	29.57	
Items that will not be reclassified to profit or loss	-	-	-	-	-	
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	51.68	21.52	0.80	103.74	29.57	
XI Paid up Capital	1,317.50	1,317.50	1,000.00	1,317.50	1,000.00	
(Face value of the share- Rs. 10 each)						
XII Other Equity	3,533.89	3,482.21	2,411.36	3,533.89	2,411.36	
XIII Earnings per share (of Rs. 10 each) (in Rupees)						
a. Basic (in Rs)	0.46	0.16	0.01	0.93	0.30	
b. Diluted (in Rs)	0.46	0.16	0.01	0.93	0.30	

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 27th May 2026
- During the Quarter ended 31.12.2025 the company has issued 31,75,000 Equity shares at the price of Rs. 36.30 per share on preferential basis in terms of Chapter V of (ICDR) regulations, 2018 And allotment of 20,25,000 warrants at the price of Rs. 36.30 per warrant against which 25% upfront money amounting to Rs 1,83,76,875 was received during
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in


Place: Hyderabad
Date: 27.05.2026

By Order of the Board
For Concord Drugs Limited
S. N. N. N.
Managing Director
DIN: 01764665

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST March 2026

[Rs. in Lakhs]

Particulars	Quarter ended			Year Ended	
	31-Mar-26 (Audited)	31-Dec-25 (un Audited)	31-Mar-25 (Audited)	31-Mar-26 (Audited)	31-Mar-25 (Audited)
I Revenue from Operations					
a. Net sales From Operations	3,788.80	1,696.63	1,039.17	7,873.68	4,524.46
b. Other Operating Income	1.08	2.12	0.48	3.44	1.44
II Other Income					
III Total Revenue (I+II)	3,789.89	1,698.75	1,039.65	7,877.13	4,525.91
IV Expenses					
a. Cost of Material Consumed	3,507.05	1,438.34	865.11	6,802.96	3,581.09
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-95.28	0.77	-74.49	-38.37	-58.05
c. Employees Benefit Expenses	175.26	123.73	123.83	497.05	463.45
d. Finance Costs	39.57	33.97	61.10	171.37	202.67
e. Depreciation and Amortisation expense	35.28	30.67	37.76	136.67	143.08
f. Other expenses	53.24	41.65	20.54	160.13	124.54
Total Expenses	3,715.13	1,569.14	1,033.85	7,729.81	4,456.77
Profit/ (Loss) before Exceptional Item and tax (III-IV)	74.76	29.61	5.80	147.32	69.14
V Exceptional Items					
VI Profit/ (Loss) before tax (V-VI)					
VII Tax Expense:	74.76	29.61	5.80	147.32	69.14
a. Current tax	21.96	7.92	1.90	41.82	35.52
b. Deferred tax charge/credit	21.66	7.15	0.31	41.98	20.29
0	0.30	0.77	1.59	-0.16	15.23
IX Profit/ (Loss) for the period (VII-VIII)	52.80	21.69	3.90	105.50	33.62
X Other Comprehensive Income					
Items that will not be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	52.80	21.69	3.90	105.50	33.62
XI Paid up Capital	1,317.500	1,317.500	1,000.000	1,317.500	1,000.000
(Face value of the share- Rs. 10 each)					
XII Other Equity	3,533.89	3,482.21	2,411.36	3,533.89	2,411.36
XIII Earnings per share (of Rs. 10 each)(in Rupees)					
a. Basic (in Rs)	(not annualised) 0.47	(not annualised) 0.16	(not annualised) 0.04	(annualised) 0.95	(annualised) 0.34
b. Diluted (in Rs)	0.47	0.16	0.04	0.95	0.34
Notes:					
1	The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.				
2	The above Consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 27.05.2026				
3	During the Quarter ended 31.12.2025 the company has issued 31,75,000 Equity shares at the price of 36.30 per share on preferential basis in terms of Chapter V of (ICDP) regulations, 2018 And allotment of 20,25,000 warrants at the price of Rs. 36.30 per warrant against which 25% upfront money amounting to Rs 1,83,76,875 was received during the period.				
4	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.				
5	The results are also available on the website of the Company www.concorddrugs.in				

Place: Hyderabad
Date: 27.05.2026


By Order of the Board
For Concord Drugs Limited
S. Anil Kumar
Managing Director
DIR: 017644665

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Statement of Audited Consolidated Cash flow for the year Ended 31.03.2026 Amount in Lakhs

Particulars	March 31,2026		March 31, 2025	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax		147.32		69.14
<u>Adjustments for:</u>				
<u>Profit on sale of ASSETS</u>				
Depreciation and amortisation expense	136.67		143.08	
Finance costs	171.37		202.67	
Interest income	-3.44		-1.44	
Provision for Gratuity				
		304.59		344.30
Operating profit before working capital changes		451.91		413.44
<u>Changes in working capital:</u> (Refer Note 40)				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Financial Assets				
Trade receivables	-1,077.67		-87.54	
Loans and Advances	0.00		-3.43	
Other Non Current assets	258.63		-219.52	
Inventories	-24.73		-234.57	
Other Current assets	-108.38		9.99	
Other bank balances	-36.78		-7.35	
Other Current financial Assets	8.34		-7.42	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	-57.35		436.42	
Borrowings				
Other current financial liabilities	-114.24		112.66	
Other current liabilities	44.88		-37.45	
Current tax liabilities, net	20.76		-1.76	
Provisions	-		19.00	
Deferred tax on amalgamation				
Cash generated from operations		-634.64		392.48
Net income tax paid		-41.98		-20.29
Net cash flow from operating activities (A)		-676.61		372.19
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-116.69		-233.27	
Proceeds from maturity of fixed deposits	-		-	
Investment				
- Subsidiaries	-		-	
- Others	3.44		1.44	
Net cash (used in) / flow from investing activities (B)		-113.25		-231.82
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	317.50		-	
Finance costs	-171.37		-202.67	
Repayment of Borrowings	48.15		67.89	
Repayment of short term Borrowings	-407.49		-8.04	
Govt Grants				
Other equity Adjustment	1,018.79		-	
Net cash flow (used in) financing activities (C)		805.58		-142.82
Net (decrease) in Cash and cash equivalents (A+B+C)		15.72		-2.45
Cash and cash equivalents at the beginning of the year		12.09		14.54
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		27.81		12.09
* Comprises:				
Balances with Banks		0.09		-
Others		27.72		12.09
		27.81		12.09

Nagi Reddy Seelam
Managing Director
DIN: 01764665




Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Statement of Audited Standalone Cash flow for the year ended 31.03.2026

Rs in Lakhs

Particulars	March31,2026		March 31, 2025	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax		144.86		64.13
<i>Adjustments for:</i>				
<i>Profit on sale of ASSETS</i>				
Depreciation and amortisation expense	135.72		141.80	
Finance costs	145.91		171.84	
Interest income	-3.44		-1.44	
Provision for Gratuity				
		278.19		312.20
Operating profit before working capital changes		423.05		376.33
<i>Changes in working capital:</i> (Refer Note 40)				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Financial Assets				
Trade receivables	-1,545.55		129.89	
Loans and Advances	-		-3.43	
Other Non Current assets	258.63		-219.52	
Inventories	77.63		-62.69	
Other Current assets	-93.06		31.49	
Other bank balances	-36.78		-7.35	
Other Current financial Assets	8.34		-7.42	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	259.63		3.92	
Borrowings				
Other current financial liabilities	-114.24		112.66	
Other current liabilities	44.72		-36.32	
Current tax liabilities, net	22.35		-1.25	
Provisions	-		19.00	
Deferred tax on amalgamation				
Cash generated from operations		-695.29		335.30
Net income tax paid		-41.34		-18.99
Net cash flow from operating activities (A)		-736.63		316.31
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-116.69		-233.27	
Proceeds from maturity of fixed deposits				
Investment				
- Subsidiaries	-		-	
- Others	3.44		1.44	
Net cash (used in) / flow from investing activities (B)		-113.25		-231.82
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	317.50		-	
Finance costs	-145.91		-171.84	
Repayment of Borrowings	49.79		128.13	
Repayment of short term Borrowings	-374.74		-42.95	
Govt Grants	-		-	
Other equity Adjustment	1,018.79		-	
Net cash flow (used in) financing activities (C)		865.44		-86.66
Net (decrease) in Cash and cash equivalents (A+B+C)		15.56		-7.17
Cash and cash equivalents at the beginning of the year		11.54		13.71
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		27.10		11.54
* Comprises:				
Balances with Banks		0.09		0.00
Others		27.01		11.54
		27.10		11.54

Nagi Reddy Seelam
Managing Director
DIN: 01764665





PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction,
Visakhapatnam, Andhra Pradesh - 530007.

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED,

Opinion


We have audited the accompanying statement of Standalone financial results of Concord Drugs Limited ('the company'), for the Quarter and year ended March 31, 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement

- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2026.

Basis for opinion

We conducted our audit in accordance with the standards on auditing ("SA" S) specified under section 143(10) of the Act. Our responsibility under those standards are further described in auditor's responsibilities for the audit of the standalone financial results section of our report. We are independent of the company in accordance with the code of ethics issued by the institute of chartered accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial results for the Quarter and year ended March 31, 2026 under the provisions of the Act and rules thereunder, and we have fulfilled our ethical responsibilities in accordance with those requirements and the ICAI's code of ethics. We believe that audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Management responsibilities for the Standalone Financial results

This statement, which includes the standalone financial results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The statement has been compiled from the related audited interim condensed standalone financial statements for the three months and year ended March 31,2026. This responsibility includes preparation and presentation of the standalone financial results for the quarter and year ended march 31,2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management and the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Standalone Ind AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone Ind AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also



- a. Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to standalone financial statements and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors in the standalone financial statements.
- d. Conclude on the appropriateness of management's and Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Emphasis of Matters:

We invite the attention in the following matters:

- 1) The company has long outstanding trade receivables of Rs. 4.14 Crores in the books of accounts for more than 2 years and the company has not provided any provision for bad/doubtful debts in the books of accounts.
- 2) Balances of trade receivables, deposits, loans and advances, advances received from the customers and trade payables are subject to confirmation from the respective parties and consequential reconciliation/adjustment arising there from, if any.
- 3) Closing stocks are subject to verification and considered in books of accounts as per the management representation.

Our conclusion is not modified in respect of these matters

Other Matters:

The annual financial results include the results for the quarter ended 31 March 2026 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our opinion on the annual financial results is not modified in respect of this matter.

For Pundarikashyam and Associates

Chartered Accountants

FRN: 011330S

SURYA PRAKASA
RAO BOMMISETTI

Digitally signed by
SURYA PRAKASA
RAO BOMMISETTI
Date: 2026.05.27
15:37:15 +05'30'

B.Surya Prakasa Rao

(Partner)

MNo: 205125

UDIN: 26205125UGEQCC4138

Place: Hyderabad

Date: 27.05.2026.



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction,
Visakhapatnam, Andhra Pradesh - 530007.

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED,

Opinion

We have audited the accompanying statement of Consolidated financial results of Concord Drugs Limited ('the company'), and its subsidiaries (the company and its subsidiaries together referred to as "Group") for the Quarter and year ended March 31, 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement

(i). includes the audited financial results of the subsidiary M/s. Proton Remedies Private Limited.


(ii). is presented in accordance with requirements of Regulation 33 of listing regulations:

and

(iii). gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the Consolidated net profit and Consolidated total comprehensive income and other financial information of the Group Company for the Quarter and year ended March 31, 2026.

Basis for opinion

We conducted our audit in accordance with the standards on auditing ("SA" S) specified under section 143(10) of the Act. Our responsibility under those standards are further described in auditor's responsibilities for the audit of the Consolidated financial Results section of our report. We are independent of the company in accordance with the code of ethics issued by the institute of chartered accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated financial results for the Quarter and year ended March 31, 2026 under the provisions of the Act and rules thereunder, and we have fulfilled our ethical responsibilities in accordance with those requirements and the ICAI's code of ethics. We believe that audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Management responsibilities for the Consolidated Financial Results

This statement, which includes the Consolidated financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The statement has been compiled from the related audited interim condensed Consolidated financial statements for the three months and year ended March 31,2026. This responsibility includes preparation and presentation of the Consolidated financial Results for the quarter and year ended march 31,2026 that give a true and fair view of the Consolidated net profit and Consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.


In preparing the Consolidated financial Results, the respective Board of Directors of the companies including in the Group are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless respective Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies including Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Ind AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also



- a. Identify and assess the risks of material misstatement of the Consolidated financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to Consolidated financial Results and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors in the Consolidated financial results.
- d. Conclude on the appropriateness of Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Consolidated financial Results including the disclosures, and whether the Consolidated results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Emphasis of Matters:

We invite the attention in the following matters:

- 1) The company has long outstanding trade receivables of Rs. 4.14 Crores in the books of accounts for more than 2 years and the company has not provided any provision for bad/doubtful debts in the books of accounts.
- 2) Balances of trade receivables, deposits, loans and advances, advances received from the customers and trade payables are subject to confirmation from the respective parties and consequential reconciliation/adjustment arising there from, if any.
- 3) Closing stocks are subject to verification and considered in books of accounts as per the management representation.

Our conclusion is not modified in respect of these matters

Other Matters:

The annual financial results include the results for the quarter ended 31 March 2026 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our opinion on the annual financial results is not modified in respect of this matter

For Pundarikashyam and Associates

Chartered Accountants

FRN: 011330S

SURYA
PRAKASA
RAO
BOMMISETTI

Digitally signed by
SURYA PRAKASA
RAO BOMMISETTI
Date: 2026.05.27
15:38:21 +05'30'

B. Surya Prakasa Rao

(Partner)

MNo: 205125

UDIN: 26205125HZCNXZ1369

Place: Hyderabad

Date: 27.05.2026